Article Sidebar

Submitted
14 August 2017
Accepted
14 August 2017
Published
15 August 2017
Download
PDF
Statistic
Read Counter : 1238 Download : 815

Main Article Content

Abstract

The objective of this study was to analyze the elevation of osteoblast activity in bone marrow mesenchymal stem cells (BM-MSCs) in osteogenic medium by physiological doses of melatonin administration by measuring alkaline phosphatase (ALP) and osteocalcin level.This studyused BM-MSCs from Rattusnorvegiccus femur bone. Rat BM-MSCs were cultured in a-Mem medium, differentiated in osteogenic medium, and administrated melatonin up to 21 days. This study was divided into 4 groups, K0 (control group), K1 (administrated of 25 nM melatonin), K2 (administrated of 50 nM melatonin), and K3 (administrated of 100 nM melatonin). Rat BM-MSCs were characterized CD 45- and CD 105+ marker using imunocytochemistry analysis and stained with Alizarin red after 15 days treatment. ALP and osteocalcin level were measured using ELISA Kit in days 21st.There weren't differences ofALP level beetwen groups and there are differences ofosteocalcin level between control groups (K0) withK1, K2, dan K3, and beetwen K1 and K2. The conclusion of this study was that there were an elevation of osteoblast activity in rat BM-MSCs in osteogenic medium by physiological doses of melatonin administration characterized by the elevation of osteocalcin level.

Keywords

melatonin BM-MSCs ALP level osteocalcin level osteoblast activity

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Yuliyanasari, N., Mastutik, G., & Putra, S. T. (2017). THE ELEVATION OF OSTEOBLAST ACTIVITY IN RAT BONE MARROW MESENCHYMAL STEM CELLS IN OSTEOGENIC MEDIUM EXPOSED WITH MELATONIN IN PHYSIOLOGICAL DOSES. Folia Medica Indonesiana, 53(1), 41–48. https://doi.org/10.20473/fmi.v53i1.5489
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Barcelo EJS, Mediavilla MD, Tan DX, Relter RJ (2010). Scientific Basis for the Potential Use of Melatonin in Bone Diseases: Osteoporosis and Adolescent Idiopathic Scoliosis. Journal of Osteo-porosis, 1-10
  2. Beederman M, Lamplot JD, Nan G, Wang J, Liu X, Yin L, Li R, Shui W, Zhang H, Kim SH, Zhang JZ, Kong Y, Denduluri S, Rogers MR, Pratt A, Haydon RC, Luu HH, Angeles J, Shi LL, He TC (2013). BMP signaling in mesenchymal stem cell differentiation and bone formation.J. Biomedical Science and Engineering 6, 32-52.
  3. Eijkenn M, Koedam M, Driel V, Buurman CJ, Pols HAP, LeeuwenJPTM. 2006.The essential role of glucocorticoids for proper human osteoblast differen-tiation and matrix mineralization. Molecular and Cellular Endocrinology34, 1-7.
  4. Elabscience (a) (2014). Rat ALP (Alkaline Phosphatase) ELISA Kit 5 th Edition. ElabscienceBiothechnology Co, Ltd. www.elabscience.com
  5. Elabscience (b) (2014). Rat OC/BGP (Osteocalcin) ELISA Kit 5 th Edition. ElabscienceBiothechnology Co, Ltd. www.elabscience.com.
  6. Gasser, JA (2003). Stem Cells in the Treatment of Osteoporosis.European Cells and Materials 6, 1-21.
  7. GolubEE, Battaglia KB (2007). The role of alkaline phosphatase in mineralization.CurrOpinOrthop,444 - 448.
  8. Lindenmair A, HatlapatkaT, KollwigG, Hennerbichler S, GabrielC, WolbankS, Redi H, KasperC (2012). Mesenchymal Stem or Stromal Cells from Amnion andUmbilical Cord Tissue and Their Potential for Clinical Applications. Cells, 1, 1061-1088.
  9. Luchetti F, Canonico B, Bartolini D, Arcangeletti M, ciffolilliS, MurdoloG, PiroddiM, PapaS, Reiter RJ, Galli, F (2014). Melatonin regulates mesenchymal stem cell differentiation: a Review. J.Pineal Res 56,382-397.
  10. Maria S, Enderby PAW (2014). Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. J.Pineal Res 56, 115-125.
  11. Nakamura A, Dohi Y, Akahane M, Ohqushi H, Nakajima H, Funaoka H, Takakura Y (2009). Osteocalcin secretion as an early marker of in vitro osteogenic differentiation of rat mesenchymal stem cells.Tissue Eng Part C Methods 15, 2, 169-180.
  12. National Osteoporosis Foundation (2014).Clinician's Guide To Prevention And Treatment Of Osteoporosis. National Osteoporosis Foundation, 1-55.
  13. Neve A, CorradoA, PaoloF, Cantatore, P (2010). Osteo-blast Physiology in normal and pathological Condition. Cell Tissue Res, 1-14.
  14. Pino AM, Rosen CJ, Rodriguez JP (2012). In Osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis. Biol Res 45, 279-287.
  15. Radio NM.; Doctor JS, Enderby PAW (2006). Melato-nin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK1/2 signaling cascade. J. Pineal Res40, 332–342.
  16. RantamFA, Ferdiansyah,danPurwati (2014).Stem Cell; Mesenchymal, Hematopoetikdan Model Aplikasi Edisi Kedua. Surabaya: Airlangga University Press, 23-40.
  17. Riggs BL, Melton LJ (1995). 3rd The Worldwide Problem Of Osteoporosis: Insights Afforded By Epidemiology Bone 17, 505–511.
  18. Roth JA, Kim BG, Lin WL, Cho M. 1999. Melatonin Promotes Osteoblast Differentiation And Bone Formation. The Journal Of Biological Chemistry 274, 31, 2041- 2247.
  19. Rucci, N (2009). Molecular biologyof bone remodel-ing.Clinical Case in Mineral and Bone Metabolisme, 5, 1, 49-56.
  20. SatomuraK, Tobiume S, Tokuyama R, Yamasaki Y, Kudoh K, MaedaE, NagayamaM (2007). Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J. Pineal Res, 1-10.
  21. ScuteriA, Donzelli, E, FoudahD, CaldaraC, RedondoJ, AmicoGD, TrediciG, Miloso M (2014). Mesengenic Differentiation: Comparison of Human and Rat Bone Marrow Mesenchymal Stem Cells. International Journal of Stem Cells 7, 1-8.
  22. Sethi S, Radio NM, Kotlarczyk MP, Chen CT, WeiYH, Jockers R, dan Enderby PAW (2010).Determination of the minimal melatonin exposure required toinduce osteoblast differentiation from human mesenchyma stem cells and these effects on downstream signaling pathways. J.Pineal Res49, 222-238.
  23. Wang Y, Zhu G, Li N, Song J, Wang L, SI X, 2015. Small molecules and their controlled release that induced the osteogenic/chondrogenic commitment os stem cells. Biotechnology advances 5, 1-15.
  24. ZaminyA, Kashani IR, BarbarestaniM, HedayatpourA, MahmoudiR, Nejad AF (2008). Osteogenic Differen-tiation of Rat Mesenchymal Stem Cells from Adipose Tissue in Comparison with Bone Marrow Mesen-chymal Stem Cells: Melatonin As a Differentiation Factor. Iranian Biomedical Journal 12, 3, 133 -141.

Most read articles by the same author(s)